Page 1

Exhibit 99.1 • • • Sotera Health Sotera Health Reports Third - Quarter and Year - to - Date 2021 Results Q3 2021 net revenues of $ 226 million increased 13 % , compared to Q3 2020 Q3 2021 net income of $ 27 million or $ 0.10 per diluted share , compared to net income of $ 0.01 million or $ 0.00 per diluted share in Q3 2020 Q3 2021 Adjusted EBITDA of $ 117 million increased 16 % , compared to Q3 2020 • Q3 2021 Adjusted EPS of $ 0.21 improved $ 0.12 compared to Q3 2020 • • • September 30 , 2021 total debt of $ 1.8 billion and total net debt of $ 1.7 billion ; net leverage ratio improved to 3.6x Narrowing full - year 2021 revenue growth outlook to 12 % - 14 % and full - year 2021 Adjusted EBITDA growth to 13 % - 14 % Full redemption of $ 100 million Senior Secured First - Lien Notes CLEVELAND , OH , November 10 , 2021 – Sotera Health Company ( " Sotera Health " or the " Company " ) ( Nasdaq : SHC ) , a leading global provider of mission - critical end - to - end sterilization solutions , lab testing and advisory services for the healthcare industry , today announced financial results for the third quarter and first nine months of 2021 . Third - quarter 2021 net revenues increased 13.1 % to $ 226 million , compared with $ 200 million in the same period a year ago . Third - quarter 2021 net income attributable to Sotera Health ( " net income ” ) was $ 27 million , or $ 0.10 per diluted share , compared with net income of $ 0.01 million , or $ 0.00 per diluted share in the third quarter of 2020. Adjusted EBITDA for the third - quarter 2021 increased 16.1 % over the third quarter of 2020 to $ 117 million . Third - quarter 2021 adjusted earnings per diluted share ( " Adjusted EPS " ) was $ 0.21 , compared to $ 0.09 in the third quarter of 2020 , an increase of $ 0.12 per diluted share . Please refer to the section " Non - GAAP Financial Measures " provided later in this release . For the first nine months of 2021 , net revenues increased 14.8 % to $ 690 million , compared to $ 601 million for the same period in 2020. Net income was $ 81 million , or $ 0.29 per diluted share for the nine months ended September 30 , 2021 , compared with net income of $ 5 million , or $ 0.02 per diluted share , for the same period last year . First nine months of 2021 Adjusted EBITDA increased 16.2 % to $ 357 million and Adjusted EPS grew by $ 0.32 to $ 0.65 compared to the first nine months of 2020. Please refer to the section " Non - GAAP Financial Measures ” provided later in this release . - are each " We are very pleased to report solid top - line , net income and Adjusted EBITDA growth for the third quarter . This represents double - digit top - line and Adjusted EBITDA growth in every quarter since the IPO , and we could not be more proud of our team for working so diligently to deliver this level of growth during this challenging and unique time , ” said Chairman and Chief Executive Officer , Michael B. Petras , Jr. " Our three business segments - Sterigenics , Nordion and Nelson Labs making solid progress executing against strategic goals . With nine months of reported financials and good visibility into the remainder of the year , we are narrowing the 2021 outlook range provided on our earnings call in August , when guidance was increased from our original March outlook . The outlook range provided today represents solid double - digit top - line and Adjusted EBITDA growth for full - year 2021. " 1